Could a simple scan predict breast cancer drug success?
NCT ID NCT06909604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new PET imaging method that uses a radioactive tracer to spot HER2 proteins on breast cancer cells. The goal is to see if the scan can predict how well patients will respond to antibody-drug conjugate therapy. Researchers will enroll 50 adults with HER2-positive or low tumors who are receiving neoadjuvant therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Al18F-HER2-BCH (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors predict which breast cancer patients will benefit from antibody-drug conjugate therapy, avoiding ineffective treatments.
What could go wrong
This is an early-stage imaging study with only 50 participants, so results may not apply to all patients. The tracer's ability to predict response is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••